Deep Dive - Season 2

Dr. Robert Zivadanov details the findings of a post-hoc assessment of the ORATORIO trial of ocrelizumab in multiple sclerosis.

Tahir Amin joins Deep Dive to discuss I-MAK’s mission to overcome anti-competitive patent tactics by originator companies so as to improve access and affordability of medicines.

Dr. James Phelps joins Deep Dive to dig up the roots of the crisis and discusses what physicians of all kinds can do to meet the nation’s mental health needs, especially through new models of collaborative care.

Dr. Brett Nowlan joins Deep Dive to discuss a recent scientific statement advocating for physical activity as a first-line treatment for slightly elevated blood pressure and cholesterol.

Chris Panebianco, Chief Marketing Officer of Bankers Healthcare Group, joins Deep Dive to discuss physician debt consolidation and management strategies.

Dr. Joshua Sabari discussed the recent FDA approval of amivantamab to treat patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Dennis O'Neill discusses the treatment potential for biosynthesized psychedelic drugs for anxiety, depression, alcoholism, and terminal illness, and how BioMediCan is changing the game by sustainably and reliably synthesizing higher-quality psychedelics in large volumes.

Dr. Jerry Bagel dives into the complex treatment world of psoriasis. He discusses comorbidities associated with the skin disease, as well as treatment advancements and hurdles, using biologics treatments during the COVID-19 pandemic, and more.

Kevin F. Boehnke, PhD, joins Deep Dive to discuss cannabidiol use for fibromyalgia - including symptom management.

Dr. George Yoo discusses the advances in telehealth brought on by the COVID-19 pandemic, some specific telehealth services provided by Karmanos Cancer Center, and walks us through what a telehealth visit might look like.

Martin VanTrieste joins Deep Dive to dig into Civica’s business and membership model, its suppliers, the progress it has made in dealing with hospital drug shortages and what motivates VanTrieste to work for free!

Two researchers join Deep Dive to discuss brain imaging, functional MRI, and future technologies.

Peter Carlos and assistant Jaycee Leonardo discuss social media and the effects social media can have on practices. After gaining 1.7 million followers on TikTok, they use what they have learned through their own personal experiences with their social media to help practices grow on social media.

Laura Bukavina, MD, MPH, and Justin Dubin, MD, discuss how findings of a recent peer-reviewed study point to a rise in academic urology programs’ engagement on Twitter for marketing purposes. They also discuss their own usage of social media and share advice for medical professionals using social media.

Pharmacy Times interviewed Michael Holden, FRPharmS, FRSPH, associate director of Pharmacy Complete in the United Kingdom, to discuss some of the key differences between the role of the pharmacist in the United Kingdom versus the United States.

Doron Schneider, VP, Population Health Services at Tandigm Health, joins to discuss how value-based care strategies helped some independent practices survive during the COVID-19 pandemic.

Laura E. Riley, MD. Riley is chair of Obstetrics and Gynecology at Weill Cornell Medicine and Obstetrician and Gynecologist-in-Chief at New York-Presbyterian Hospital in New York City. She specializes in obstetric infectious disease and is a member of the American College of Obstetricians and Gynecologists (ACOG) COVID-19 Task Force.

Gale Simons-Poole updates us on the Paycheck Protection Program and what small business owners—including dentists and clinicians—need to know about loan forgiveness. Topics include the basics of PPP loan forgiveness, what borrowers need to qualify, common misconceptions about PPP forgiveness, and some of the most common mistakes that borrowers make when applying for PPP loan forgiveness.

As disparities in health care coverage and access have become spotlighted amid the COVID-19 pandemic, health economics and outcomes research (HEOR) may play a significant role in addressing gaps present in disadvantaged communities and the health care system. Dr. Amy Abernethy speaks on recent innovations within HEOR, how the FDA used data in their response to the pandemic, and the current state of the agency amid an ongoing search for a new FDA Commissioner.

In this edition of Deep Dive, Jonathan E. Alpert, MD, PhD discusses mood disorders and the surprising symptoms that male patients may present.

Andy Pawson discusses new contact lenses his company, Alcon, created.

Dr. Emad Rizk, CEO and president of analytics company Cotiviti discusses value-based care success, how close provider-payer partnerships can help deliver the right care, and technology available to help make the most of value care models.

Pharmacy Times interviewed Jay Lieberman, MD, a pediatric infectious disease specialist and senior medical director of PRA Health Sciences to discuss the future of COVID-19 disease and vaccines for adolescents and children, specifically in light of his perspective on the enrollment of his twin daughters in the Moderna COVID-19 vaccine trial.

Dr. Rupa Wong, Rupa Wong, MD, an ophthalmologist practicing at Honolulu Eye Clinic, weighs in on myopia in children, discusses how the pandemic impacted eye health in children, and best practices to maintain optimal eye health as children get ready for the new school year.

David Hyun joins After Hours to discuss the issue of antibiotic resistance and minimizing inappropriate prescribing of antibiotics so as to slow the spread of “superbugs".

In this Deep Dive, Omar Reda, MD, discusses how clinicians of all kinds can recognize and treat trauma.

Doctor Heather M. Gilmartin talks about ways the infection prevention profession can lure more young health care professionals into its ranks.

Martin S. Tallman, MD, a Professor of Medicine at Weill Cornell Medical College and the Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses his role as President of the American Society of Hematology, as well as developments and challenges facing the hematologic oncology field.